With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.
Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden, and extensive networks and footprint in Greater China, Asia, USA and Europe.
A signatory to the UN PRI and committed to promoting sustainable development and impact investment.
BOCG's portfolio company, HighTide Therapeutics, today announced that two Phase 3 trials of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. HighTide plans to submit a new drug application for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) later this year.Congratulations toHighTide Therapeutics on achieving another important milestone in the clinical development of HTD1801. Looking forward to HighTide Therapeutics bringing safer and more effective treatment options to the large population of type 2 diabetes patients!
On January 10th, 2025, BOCG's portfolio company, Ribo Life Science, with its subsidiary, Ribocure Pharmaceuticals AB, announced that they have achieved a key pre-clinical milestone in their siRNA programs, less than a year into their collaboration with Boehringer Ingelheim with an overall deal value that exceeds USD 2 billion.
On December 6, 2024, the 7th Venture Capital Responsible Investment Forum was successfully held in Lujiazui, Shanghai. Frank Yang, Founding Partner and CEO of BOCG, was invited to join the roundtable discussion on “Healthcare Innovation and Well-Being”, engaging in in-depth dialogue with fellow participants.